Tiotropium in Patients with Bronchiectasis: A Prospective Cohort Study

Shi, Zu-Liang; Zhang, Hongying; Peng, Haibo; Zhu, Zhongming

doi:10.1007/s00408-023-00597-8

Cited by 4 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported the benefits of bronchodilators in patients with bronchiectasis and airflow limitation and have proposed a role for inhaled corticosteroids based on blood eosinophil counts. 38 39 Further studies are needed to determine the optimal treatment for patients with tuberculosis-associated COPD.…”

Section: Discussionmentioning

confidence: 99%

Risk factors of acute exacerbation and disease progression in young patients with COPD

Bae,

Lee,

Choi

et al. 2024

BMJ Open Resp Res

View full text Add to dashboard Cite

ObjectiveWe aimed to elucidate the clinical factors associated with acute exacerbation and disease progression in young patients with chronic obstructive pulmonary disease (COPD).MethodsThis retrospective longitudinal observational study included patients with COPD aged between 20 and 50 years with post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)<0.7. Eligible patients were followed up with ≥2 spirometry examinations at 1 year interval after COPD diagnosis. The primary outcome was moderate-to-severe acute exacerbation in young patients with COPD. Secondary outcomes were early initiation of regular inhalation therapy and accelerated annual post-bronchodilator FEV1decline.ResultsA total of 342 patients were followed up during a median of 64 months. In multivariable analyses, risk factors for moderate-to-severe exacerbation were history of asthma (adjusted HR (aHR)=2.999, 95% CI=[2.074–4.335]), emphysema (aHR=1.951, 95% CI=[1.331–2.960]), blood eosinophil count >300/µL (aHR=1.469, 95% CI=[1.038–2.081]) and low FEV1(%) (aHR=0.979, 95% CI=[0.970–0.987]). A history of asthma, sputum, blood eosinophil count >300/µL, low FEV1(%) and low diffusing capacity of the lung for carbon monoxide (DLCO) (%) were identified as clinical factors associated with the early initiation of regular inhalation therapy. The risk factors associated with worsened FEV1decline were increasing age, female sex, history of pulmonary tuberculosis, sputum, low FEV1(%) and low DLCO(%).ConclusionsIn young COPD patients, specific high-risk features of acute exacerbation and disease progression need to be identified, including a history of previous respiratory diseases, current respiratory symptoms, blood eosinophil counts, and structural or functional pulmonary impairment.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors of acute exacerbation and disease progression in young patients with COPD

Bae,

Lee,

Choi

et al. 2024

BMJ Open Resp Res

View full text Add to dashboard Cite

show abstract

“…In the present issue of LUNG, Shi et al [13] conducted an observational study in a prospective cohort including 169 patients with bronchiectasis and airflow obstruction who were not taking LABA or ICs and were followed for 12 months. They found, as in the Jayaram study, a significant improvement in lung function, but in this case they Pneumology Department, Hospital Universitario y Politécnico La Fe, Bulevar Sur s/n, 46012 Valencia, Spain also observed a reduction in the adjusted risk of moderate exacerbations and a longer time before the first-time severe exacerbation in those patients who took tiotropium.…”

mentioning

confidence: 99%